Institutional members access full text with Ovid®

Survival following HIV infection of a cohort followed up from seroconversion in the UK

Ewings, Fiona Ma; Bhaskaran, Krishnana; McLean, Kenb; Hawkins, Davidc; Fisher, Martind; Fidler, Sarahe; Gilson, Richardf; Nock, Demelzaa; Brettle, Rayg; Johnson, Margareth; Phillips, Andrewi; Porter, Kholouda; for the UK Register of HIV Seroconverters

doi: 10.1097/QAD.0b013e3282f3915e
Epidemiology and Social

Objectives: To estimate changes over calendar time in survival following HIV seroconversion in the era of HAART and to provide updated survival estimates.

Methods: Using data from a UK cohort of persons with well estimated dates of HIV seroconversion, we analysed time from seroconversion to death from any cause using Cox models, adjusted for prognostic factors. Kaplan–Meier methods were then used to determine the expected survival in each calendar period.

Results: 2275 seroconverters were included with 18 695 person-years of follow up. A total of 444 (20%) died. The relative risk of death, compared with pre-1996, decreased over time to 0.63 [95% confidence interval (CI), 0.48–0.81], 0.24 (0.17–0.34), 0.14 (0.10–0.21), 0.08 (0.05–0.13) and 0.03 (0.02–0.06) in 1996–1997, 1998–1999, 2000–2001, 2002–2003 and 2004–2006, respectively. An elevated risk of death was associated with older age at seroconversion [hazard ratio (HR), 1.49; 95% CI, 1.34–1.66 per 10-year increase] and HIV infection through injecting drug use (HR, 1.53; 95% CI, 1.17–2.00). In 2000–2006, the proportion of individuals expected to survive 5, 10 and 15 years following seroconversion was 99%, 94% and 89%, respectively.

Conclusions: Survival following HIV seroconversion has continued to improve over calendar time in our cohort, even in the more recent years of HAART availability. HIV seroconverters, by definition identified early in their infection, are likely to have the greatest opportunity for intervention; if similar high survival expectations are to be seen in the wider HIV-infected population, early diagnosis is likely to be crucial.

From the aMRC Clinical Trials Unit, London, UK

bThe West London Centre for Sexual Health, London, UK

cChelsea & Westminster NHS Trust, London, UK

dBrighton & Sussex University Hospitals NHS Trust, Brighton, UK

eSt. Mary's Hospital, London, UK

fUCL Centre for Sexual Health & HIV Research and the Mortimer Market, Centre, Camden Primary Care Trust, London, UK

gThe Lothian University Hospitals NHS Trust, Edinburgh, Scotland, UK

hRoyal Free NHS Trust and Royal Free & University College Medical School (RFUCMS), London, UK

iDepartment of Primary Care & Population Sciences, RFUCMS, London, UK.

* See Appendix for full list of authors.

Received 5 July, 2007

Accepted 20 September, 2007

Correspondence to Dr K. Porter, MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK. Tel: +44 (0) 207 670 4715; fax: +44 (0) 207 670 4818; e-mail:

© 2008 Lippincott Williams & Wilkins, Inc.